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Objectives This study aimed to determine the pre-implantation predictors for in-hospital mortality in children with ventricu-
lar assist device (VAD) support.
Background Candidate selection is of critical importance for improved outcomes in patients supported with VAD. However,
risk factors for post-VAD survival in children are still not clearly understood.
Methods From June 1996 to December 2009, 92 children underwent implantation of a long-term VAD at Germany Heart
Institute Berlin. Data on all these patients were retrospectively analyzed, and pre-operative risk factors for in-
hospital survival after VAD implantation were identified by multivariate logistic regression.
Results Of the 92 subjects, the median age at implantation was 7 years (range 12 days to 18 years), and the median
support time was 35 days (range 1 to 591 days). The overall survival rate to transplantation or recovery of ven-
tricular function was 63%. Independent predictors of in-hospital mortality in children included congenital etiology
(odds ratio [OR]: 11.2; 95% confidence interval [CI]: 2.6 to 47.5), norepinephrine requirement (OR: 6.9; 95% CI:
1.4 to 31), C-reactive protein level 6.3 mg/dl (OR: 4.9; 95% CI: 1.1 to 22.1), and central venous pressure
17 mm Hg (OR: 4.6; 95% CI: 1.1 to 20).
Conclusions Congenital etiology, pre-operative norepinephrine requirement, higher serum C-reactive protein, and central ve-
nous pressure were associated with increased in-hospital mortality in children with VAD support. Optimal candi-
date selection and timing of VAD insertion may be of great importance for improved outcomes in children with
advanced heart failure. (J Am Coll Cardiol 2011;58:1183–90) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.017Ventricular assist device (VAD) is a standard therapy to
provide long-term mechanical circulatory support in pa-
tients with end-stage heart disease as either a bridge to heart
transplantation or an alternative to transplantation that
could improve the functional status, quality of life, and
survival of the recipients. Over the past decade, there have
been significant advancements in VAD technology and
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accepted June 7, 2011.growing overall experience with VAD support in the pedi-
atric population that yielded greatly improved survival.
Previous research based on adult recipients indicated that
appropriate timing and candidate selection are extremely
critical for effective use of mechanical circulatory support
(1,2). In the literature, several pediatric VAD studies have
reported risk factors for the post-operative survival of
children (3,4). Nevertheless, the patients included in these
studies were mainly adolescents with adult-size devices
implanted, and the number of patients receiving long-term
VAD support was relatively small, which might limit the
generalizability of their results to the pediatric population.
More important, these studies included a limited analysis of
patient characteristics; therefore, many potentially impor-
tant pre-operative risk assessment parameters might have
been missed. Because of the increased use of VAD support
in pediatric patients with advanced heart failure, risk factors
and clinical indications for VAD implantation in this
population need to be further clarified. In the present study,
we retrospectively analyzed our pediatric VAD experience to
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VAD implantation in pediatric
patients with advanced heart
failure.
Methods
Study population. Pediatric sub-
jects 18 years of age and younger
who underwent an initial implan-
tation of a long-term VAD at
Germany Heart Institute Berlin
between June 1996 and December
2009 (N  92) were identified
retrospectively from a computer-
ized database. All these children
had end-stage heart failure at the
time of VAD insertion and were supported with intravenous
inotropic agents or low-output syndrome developed after a
cardiac surgery that required subsequent implantation of a
VAD to separate them from cardiopulmonary bypass. All
parents of the patients provided written informed consent
for device implantation. The study population was followed
until heart transplantation, myocardial recovery, or death on
mechanical support. Approval by the ethics committee of
the present study was not required, because the retrospective
data analysis did not vitiate human rights, according to the
German law.
Ventricular assist devices. During the study period, mul-
iple VADs were inserted in the pediatric patients with
dvanced heart failure. Implanted pumps included the
erlin Heart EXCOR VADs (Berlin Heart GmbH, Berlin,
ermany) (n  87, 95%), the Berlin Heart Incor VADs
(Berlin Heart GmbH, Berlin, Germany) (n  2, 2%), the
Novacor VADs (World Heart Inc., Oakland, California)
(n  2, 2%), and the HeartWare VAD (HeartWare Inc.,
Miramar, Florida) (n 1, 1%). For small infants and young
children, the Berlin Heart EXCOR pediatric VADs were
implanted, which were designed specifically to provide
mechanical circulatory support in all age groups of the
pediatric population. The adult-sized VADs (Incor, Nova-
cor, and HeartWare) were only used in the fully grown
adolescent patients. Detailed information concerning the
surgical procedure of VAD insertion, implantation and
weaning criteria, and post-operative anticoagulation therapy
was described in previous reports (5–7).
Statistical analysis. Because most of the in-hospital deaths
occurred during the first 3 months after VAD implanta-
tion, we chose 90-day in-hospital mortality as the pri-
mary endpoint for the risk factor analysis (data are shown
in the Online Appendix). Subsequently, subjects were
categorized into 2 groups: children who survived during
the first 3-month hospitalization after VAD implantation
(n  62) and those who did not (n  30). Patients’
medical records were retrospectively reviewed, and the
Abbreviations and
acronyms
BVAD  biventricular
assist device
CHD  congenital heart
disease
CI  confidence interval
CRP  C-reactive protein
CVP  central venous
pressure
LVAD  left ventricular
assist device
OR  odds ratio
VAD  ventricular assist
devicedemographic, clinical, echocardiographic, hemodynamic,and laboratory data were obtained and assessed. Details
of data collection are shown in the Online Appendix.
Data were analyzed with PASW Statistic 18 (SPSS Inc.,
Chicago, Illinois). Categorical variables were described
by percentages and frequencies, and numerical variables
were represented as mean  SD and/or median range(s).
Qualitative data were compared using the chi-square or
Fisher exact test, as appropriate. For continuous data,
between-group comparisons were performed by either
the Mann-Whitney or the Student t test, depending on
the normality of each variable. All statistical comparisons
were 2 sided. The variables that were significant by
univariate analysis were used as potential risk factors for
the stepwise multivariable model, with an entry criterion
of a p value 0.1; receiver-operating characteristic curves
were applied to identify cutoff values for continuous
variables in this series that best predicted post-VAD
mortality. The Kaplan-Meier method was applied to
estimate survival probability for children continuing on
mechanical support, and log-rank analysis was performed
to assess the statistical significance of survival difference.
Patient survival was calculated from the day of VAD
implantation until death on mechanical support, censor-
ing the time of heart transplantation or recovery of the
native heart. Competing outcomes methods were applied
to analyze outcome after implantation.
Results
Patient characteristics. From June 1996 to December
2009, 44 girls and 48 boys were implanted with a long-term
Patient Characteristics,Clinical Outcom s, and Adverse Events (N  92)Table 1 Pa ient Characteristics,Clinical Outcomes, and Adverse Events (N  92)
Patient characteristics
Age, yrs 7 (0.03–18.00)
Male 48 (52)
Weight, kg 18.8 (3.2–115.0)
Body surface area, m2 0.8 (0.2–2.4)
Body mass index, kg/m2 15.3 (8.6–33.6)
Pre-operative ICU stay, days 88 (96)
Bridge to VAD 17 (18)
Mechanical ventilation support 67 (73)
Renal replacement therapy 11 (12)
Pre-operative CPR 30 (33)
Implantation year before 2005 43 (47)
Clinical outcomes
Transplantation 42 (46)
Recovery 16 (17)
Death 34 (37)
Adverse events
Infection 34 (37)
Bleeding 24 (26)
Stroke 22 (24)
Pump change 19 (21)
Renal failure 17 (19)Values are median (range) or n (%).
CPR cardiopulmonary resuscitation; ICU intensive care unit; VAD ventricular assist device.
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VAD insertion, the median age was 7 years (mean 7.4 years;
range 12 days to 18 years). The median weight was 18.8 kg
(mean 27.5 kg; range 3.22 to 115 kg), and the mean body
surface area was 0.91 m2 (median 0.80 m2; range 0.2 to 2.38
2). Of the 92 pediatric patients, 66 (72%) had a diagnosis
of cardiomyopathy, 21 (23%) congenital heart disease
(CHD), and 5 (5%) acute myocarditis. The diagnoses of
CHD included transposition of the great arteries (n  10),
complete atrial ventricular septal defect (n  3), anomalous
left coronary artery arising from the pulmonary artery (n 
2), single ventricle (n  2), Ebstein’s anomaly (n  1),
hypoplastic left heart syndrome (n  1), interrupted aortic
arch (n  1), and atrial septal defect, ductus arteriosus with
left ventricular tumor (n  1).
Clinical outcomes. Of the 92 patients analyzed, 42 pa-
tients were successfully bridged to heart transplantation, and
16 were explanted after myocardial recovery. The overall
survival rate to transplantation or recovery of ventricular
function was 63%. The Kaplan-Meier estimates of survival
on mechanical support were 76  4.7% and 56.7  6.4% at
30 days and 6 months after VAD implantation, respectively
(Fig. 1). Fifty-eight children were finally discharged from
the hospital. Of the 34 deaths in patients with a VAD, 32
patients died before hospital discharge (34.8% in-hospital
mortality), and 93.8% of these (30 of 32) occurred within 90
days of VAD implantation (Fig. 2). Among these children,
the main causes of post-operative deaths included multisys-
tem failure in 11 children (36.7%), stroke in 5 (16.7%),
bleeding in 4 (13.3%), circulatory failure in 3 (10%),
respiratory failure in 3 (10%), infection in 2 (6.7%), and
other causes in 2 (6.7%).
The median time of mechanical circulatory support was 35
days (mean 67 days; range 1 to 591 days). Post-operative
adverse events included infection in 34 patients (37%), bleed-
Figure 1 Kaplan-Meier Analysis of Post-VAD Survival in Childre
Post-implantation survival curves for all patients. VAD  ventricular assist device.ing requiring reoperation in 24 (26.1%), stroke in 22 (23.9%),
pump exchange in 19 (20.7%), and renal failure in 17 (18.5%).
Subgroup analysis. VAD SUPPORT IN YOUNG CHILDREN.
In the present study, 43 patients younger than 5 years of age
were on VAD support. The median weight was 7.2 kg (mean
7.8 kg; range 3.2 to 18 kg), and the median body surface area
was 0.38 m2 (mean 0.39 m2; range 0.20 to 0.72 m2). Eighteen
atients were successfully bridged to transplantation, and 12
ere weaned from VAD support with cardiac recovery. The
verall survival rate to transplantation or recovery of ventricular
unction was 69.8%, which was similar to that in older
hildren. We did an additional analysis by only including
atients weighing 10 kg; a total of 22 of the 32 children
68.8%) successfully survived during the support period.
VAD SUPPORT IN CHILDREN WITH CHD. Twenty-one pa-
ients with CHD underwent long-term VAD implantation.
f the 21 CHD patients, 15 died before VAD explantation
71%) compared with 19 of the 71 children with a noncon-
enital etiology (27%). The 30-day and 6-month survival rate
as 86.1  4.3% and 68.9  6.8% for patients with noncon-
enital heart disease and 40.2 12.2% and 16.1 10.1% for
hildren with CHD, respectively. Compared with patients
ith CHD, noncongenital recipients had a significantly
etter survival rate (p  0.0001).
BIVENTRICULAR VAD VERSUS LVAD. Thirty-two patients re-
eived biventricular support with a biventricular VAD
BVAD). During mechanical support, 16 of 32 patients with a
VAD (50%) and 18 of 60 (30%) of patients with a left
entricular assist device (LVAD) died. The Kaplan-Meier
stimates of 30-day and 6-month survival were 82.9  5.3%
nd 67.8  7.5% for LVAD implantation, respectively, and
3.5  8.9% and 37.9  10.5%, respectively, for children
equiring biventricular support (p  0.02).
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MECHANICAL CIRCULATORY SUPPORT. Nine patients were
upported by extracorporeal membrane oxygenation, 4 un-
erwent implantation of an intra-aortic balloon pump, and
received temporary support from centrifugal pumps as a
ridge to VAD. Four of them were bridged to heart
ransplantation, 4 were weaned from VAD support with
yocardial recovery, and 9 patients died before VAD
xplantation. The overall survival rate to transplantation or
yocardial recovery was 47.1%.
re-operative predictors of in-hospital mortality. PATIENT
HARACTERISTICS AND PRE-OPERATIVE INTRAVENOUS
EDICATION. Table 2 shows the patient characteristics and
re-operative medication use of the study population. When
ichotomizing the etiology of heart failure into congenital or
oncongenital (cardiomyopathy or myocarditis), the incidence
f in-hospital death for patients with CHD was significantly
igher than for those without congenital lesions (p 0.0001).
revious cardiac surgery was associated with significantly in-
reased in-hospital mortality (p  0.001). There was signifi-
antly increased mortality after VAD insertion in children
eceiving pre-operative intravenous norepinephrine infusion
p  0.008). Additionally, death during mechanical support
as less common in patients supported with pre-operative
ilrinone (p  0.04).
VITAL CLINICAL SIGNS AND HEMODYNAMIC DATA. In Table 3,
he results for comparisons of clinical signs and hemody-
amic indexes between the 2 groups are presented. Among
hose pre-operative hemodynamic variables, elevated central
enous pressure (CVP) was the single parameter that
Figure 2 Competing Outcomes Analysis in Children After VAD I
Cumulative proportion of pediatric recipients who died or underwent transplantatioortended an increased risk of in-hospital mortality (p .02). Several hemodynamic parameters could vary ac-
ording to different age (such as systematic blood pres-
ure, heart rate, and cardiac output). An additional
nalysis was done by separately assessing these factors in
nfants (younger than 1 year), younger children (1 to 5
ears of age), and older children (5 years of age and
lder). The effects of the variables were not statistically
ignificant in each subgroup.
PRE-OPERATIVE LABORATORY MEASUREMENT. Table 4
ummarizes the laboratory profile of the study cohort. There
as increased mortality in children with a higher C-reactive
rotein (CRP) level (p  0.04). There was no significant
ifference in other laboratory parameters between the sur-
ivor and nonsurvivor groups.
ultivariate logistic regression. Variables that were uni-
ariately significant were further entered into a multivariable
ogistic regression model. Independent predictors associated
ith increased mortality in pediatric patients after VAD
nsertion included congenital etiology (odds ratio [OR]:
1.2; 95% confidence interval [CI]: 2.6 to 47.5; p  0.001),
a norepinephrine requirement (OR: 6.9; 95% CI: 1.4 to 31;
p  0.02), CRP level 6.3 mg/dl (OR: 4.9; 95% CI: 1.1 to
22.1; p 0.041), and CVP17 mm Hg (OR: 4.6; 95% CI:
1.1 to 20; p 0.04) (Table 5). The Hosmer and Lemeshow
test showed that this model provided good fit with the data
(p  0.89). The multicollinearity analysis indicated that our
risk factors were not confounded by the multicollinearity
between these parameters (variance inflation factor ranged
from 1.02 to 1.07).
The present analysis demonstrated that children with
ntation
very, or ongoing support. VAD  ventricular assist device.mpla
n, recosevere right heart failure needing BVAD implantation had
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creased milrinone use (p  0.001) and increased dose of
pinephrine use (p  0.001) were associated with require-
ent for BVAD support. The study period spans 13 years,
uring which significant improvement in the field of pedi-
tric mechanical circulatory support has been achieved,
hich might also cause potential bias to our analysis.
urthermore, pump size, CHD, and patient age/size tended
o be correlated in pediatric patients; thus, potential con-
ounding between these factors could exist. We evaluated
he possible confounding by these factors in logistic regres-
ion models that included each of these covariates (biven-
ricular support, implantation year, and pump size). All of
he identified risk factors remained statistically significant
fter adjustment for the potential confounding factors, and
he effects of these confounding factors were not significant
Pre-Operative Characteristics and Intravenous MTable 2 Pre-Operative Characteristics and I
Su
(n
Pre-operative characteristics
Age, yrs 5 (
Male 29 (
Weight, kg 18.2 (
BSA, m2 0.7 (
Body length, cm 105
BMI, kg/m2 15.6 (
CHD 7 (
Previous sternotomy 13 (
Pre-operative ICU stay 59 (
Length of pre-operative ICU stay, days 1.4 (
Bridge to VAD 11 (
ECMO 7 (
IABP 2 (
Centrifugal pump 2 (
Mechanical ventilation support 42 (
Time on ventilator support, days 1.5 (
Renal replacement therapy 6 (
Pre-operative CPR 17 (
Implantation year before 2005 27 (
Pre-operative intravenous medication*
Inotrope
1 inotrope 28 (
Milrinone 42 (
Dobutamine 20 (
Dopamine 26 (
Epinephrine 42 (
Norepinephrine 4 (
Vasodilator
Nitroprusside 20 (
Nitroglycerin 5 (
Antiarrhythmic medication
Amiodarone 10 (
Values are median (range) or n (%). *Pre-operative medication records
group).
BMI  body mass index; BSA  body surface area; CHD  co
IABP  intra-aortic balloon pump; other abbreviations as in Table 1.n the multivariate analysis. iscussion
ptimal patient selection for VAD therapy is the key to
mproved survival in patients with end-stage heart disease.
lthough many risk factors have been previously reported
ased on adult recipients, the predictors of post-VAD survival
n children have not been adequately defined. Compared with
revious pediatric VAD reports from either our institution or
ther clinical heart centers in the world, the current study
ncluded the largest number of children on long-term VAD
upport, and we have collected more complete patient profiles
iming at identifying potential factors that were closely corre-
ated with outcomes of pediatric VAD surgery (3–8). Our
nalysis showed that pre-operative characteristics associated
ith increased risk of in-hospital death were the congenital
tiology, pre-operative norepinephrine requirement, CRP level
ation Requirementsenous Medication Requirements
s
)
Nonsurvivors
(n  30)
p Value
Univariate
8.0) 8.5 (0.04–18.0) 0.51
19 (63) 0.14
5.0) 21.1 (3.2–80.0) 0.70
4) 0.9 (0.2–2) 0.61
90) 123 (50–181) 0.56
.6) 14.7 (8.6–24.7) 0.31
14 (47) 0.0001
17 (57) 0.001
29 (97) 1.00
.9) 1 (0.1–23.8) 0.77
6 (20) 0.79
2 (7)
2 (7)
2 (7)
25 (83) 0.12
.0) 0.7 (0.2–23.7) 0.69
5 (17) 0.33
13 (43%) 0.13
16 (53) 0.38
9 (32) 0.22
13 (46) 0.04
5 (18) 0.15
13 (46) 0.74
23 (82) 0.19
8 (29) 0.008
11 (39) 0.55
4 (14) 0.45
5 (18) 0.51
issing for 3 children (1 in the survivor group and 2 in the nonsurvivor
l heart disease; ECMO  extracorporeal membrane oxygenation;edicntrav
rvivor
 62
0.03–1
47)
3.6–11
0.2–2.
(53–1
9.8–33
11)
21)
95)
0.1–22
18)
11)
3)
3)
68)
0.1–17
10)
27%)
44)
46)
69)
33)
43)
69)
7)
33)
8)
16)
were m
ngenita6.3 mg/dl, and CVP 17 mm Hg.
O2  p
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Transplantation and other multicenter studies have demon-
strated significantly worse outcomes in children with CHD
Pre-Operative Vital Clinical Signs and HemodynaTable 3 Pre-Operative Vital Clinical Signs an
Vital clinical signs
Temperature, °C
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Arterial pressure, mm Hg
Central venous pressure, mm Hg
17 mm Hg
Heart rate, beats/min
SpO2, %
LVEF, %
Cardiopulmonary hemodynamics*
PA systolic pressure, mm Hg
PA diastolic pressure, mm Hg
PA pressure, mm Hg
Pulmonary capillary wedge pressure, mm Hg
Cardiac output, l
Cardiac index, l/min/m2
Pulmonary vascular resistance, dynes·s1·cm5
Systemic vascular resistance, dynes·s1·cm5
Values are mean  SD, n (%), or median (range). *Pre-operative h
43 children.
LVEF  left ventricular ejection fraction; PA  pulmonary artery; Sp
Pre-Operative Laboratory MeasurementTable 4 Pre-Operative Laboratory Measurem
Sodium, mmol/l
Potassium, mmol/l
Glucose, mg/dl
Hemoglobin, g/dl
Hematocrit, %
WBC count, k/mm3
Platelets, k/mm3
INR
PTT, s 4
ALT, IU/l 3
AST, IU/l 7
LDH, IU/l 4
CK-MB, IU/l 2
GGT, IU/l 4
Total bilirubin, mg/dl
BUN, mg/dl
Creatinine, mg/dl
Estimated creatinine clearance, ml/min/1.73 m2
Total protein, g/l
Albumin, g/dl
CRP, mg/dl
6.3 mg/dl
Values are mean  SD, median (range), or n (%).
ALT  alanine transaminase; AST  aspartate aminotransferase; BC-reactive protein; GGT  -glutamyl transpeptidase; INR  internationa
thromboplastin time; WBC  white blood cell.undergoing heart transplantation compared with other pediat-
ric patients (9,10). Similarly, in this study, the presence of a
congenital diagnosis was associated with the highest negative
Datamodynamic Data
urvivors
n  62)
Nonsurvivors
(n  30)
p Value
Univariate
6.7 1.4 37.3 2.0 0.17
0.5 17.9 77.3 19.5 0.45
1.4 11.5 47.4 11.0 0.13
0.9 12.3 58.1 11.8 0.32
2.5 6.0 16.2 7.4 0.02
10 (16) 11 (37) 0.03
5.9 29.4 128.5 38.9 0.76
(85–100) 97 (49–100) 0.29
4.5 15.4 20.8 8.6 0.48
5.3 14.2 38.4 14.8 0.13
6.3 10.3 22.1 12.6 0.24
3.4 12.1 28.6 13.8 0.23
4.0 8.9 23.1 13.2 0.86
3.0 1.0 3.1 1.5 0.86
2.3 0.8 2.8 0.9 0.23
12 146 268.0 29.7 0.65
5.2 427.2 769.0 323.7 0.26
amic assessments with cardiac catheterization were performed in
ulse oxygen saturation.
rvivors
 62)
Nonsurvivors
(n  30)
p Value
Univariate
 7.2 137.8 5.4 0.39
 0.7 4.1 0.6 0.86
0–611) 146 (81–381) 0.21
 1.9 11.6 1.5 0.40
 5.9 33.8 5.4 0.33
 6.5 14.8 7.8 0.27
 114.9 224.4 143.8 0.83
 1.1 1.8 0.9 0.24
6.2–427.0) 45.0 (27.4–200.0) 0.64
–1,886) 28 (5.0–724.3) 0.12
4–7,118) 77 (15–1,216) 0.75
22–5,750) 443 (196–5,576) 0.60
–533) 25 (6–740) 0.68
.4–169) 19.4 (4–255) 0.99
.2–7.1) 1.7 (0.4–23.1) 0.08
 37.8 72.0 46.9 0.13
.2–4.0) 1.1 (0.2–3.0) 0.26
 46.3 69.4 35.9 0.27
 1.2 5.6 0.9 0.08
 0.7 3.1 0.7 0.24
.03–22.2) 3 (0.2–19.0) 0.04
(13) 9 (30) 0.04
blood urea nitrogen; CK-MB  creatine kinase-myosin bound; CRP micd He
S
(
3
8
5
6
1
12
98
2
4
2
3
2
2
1,11
emodynent
Su
(n
136.4
4.2
137 (7
12.0
35
13.0
231.1
1.8
6.1 (2
8.5 (3
4.5 (1
71 (1
6.5 (4
1.5 (5
1.0 (0
56.4
0.9 (0
80.2
6.0
3.3
1.7 (0
8
UN 
l normalized ratio; LDH  lactate dehydrogenase; PTT  partial
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September 6, 2011:1183–90 Predictors of Post-VAD Survival in Pediatricsimpact on survival in children after VAD implantation, with a
67% in hospital mortality rate in children with CHD com-
pared with 23% in those with a noncongenital etiology. Others
have found similarly poorer outcomes in CHD patients receiv-
ing VAD support (3,4). There might be several reasons for the
reduced survival in this patient group: first, the pre-operative
cardiac lesions and physiological states of CHD patients could
be more complex and considerably worse than those in the
noncongenital population. In addition, children with CHD are
more likely to have received repeated surgical interventions to
repair cardiac anomalies before VAD implantation, thus in-
creasing the operative risk encountered on repeat sternotomy.
The pre-implantation need for vasopressor support could
be a reflection of more advanced hemodynamic instability in
these patients. Currently, the American College of Cardi-
ology/American Heart Association guidelines recommend
dopamine and norepinephrine as the first-line vasopressor
agents in the treatment of cardiogenic shock and the use of
norepinephrine, in particular, for only the most severely
hypotensive patients; thus, children requiring norepineph-
rine administration could have a worse pre-operative circu-
latory status and more advanced stage of disease compared
with others (11). A previous study also showed that a higher
dose norepinephrine requirement was associated with sig-
nificantly increased mortality in patients with refractory
cardiogenic shock (12).
CRP, one of the most sensitive markers of inflammation
and infection, has also been recently indicated as a potential
risk factor for cardiovascular disease in pediatric and adult
patients (13–15). A subgroup analysis of the Framingham
study demonstrated that older patients with serum CRP
levels 5 mg/dl experienced significantly increased risk of
chronic heart failure (14). In pediatric patients with heart
failure, an elevated CRP level was reported to be correlated
with more severe symptoms and worse cardiac characteris-
tics (15). The 2 recent cohort analyses including adult VAD
recipients both showed that higher CRP levels were asso-
ciated with significantly increased post-VAD mortality
(16,17). Consistent with their findings, our study high-
lighted increased CRP as an incremental predictor for death
in children after VAD implantation.
Increased CVP could be a reflection of the worsening
right ventricular function in patients with cardiovascular
disease and has been reported to be predictive of the
development of post-implantation right heart failure. Right
Multivariate Analysis ofPred ctors of 90-Day In-Hospital MortalityTable 5 Multivariate Analysis fPredictors of 90-Day In-Hospital Mortality
OR 95% CI p Value
Congenital etiology 11.2 2.6–47.5 0.001
Pre-operative norepinephrine requirement 6.9 1.4–31.0 0.02
C-reactive protein 6.3 mg/dl 4.9 1.1–22.1 0.04
Central venous pressure 17 mm Hg 4.6 1.1–20.0 0.04
CI  confidence interval; OR  odds ratio.heart failure in adults and children is associated with highpost-VAD morbidity and mortality, likely due to the impact
of a dysfunctional right ventricle on hepatic and renal
function and, therefore, overall operative risk. In this anal-
ysis, pediatric patients with increased CVP had a signifi-
cantly higher risk of death. Corroborating our finding, a
cohort study of adult VAD recipients by Rao et al. (18) also
identified increased CVP as an independent predictor of
post-VAD mortality.
Although currently there are no consensus guidelines for
pediatric VAD implantation, it should be used selectively to
ensure reasonable benefits for the associated risks of this
therapy. In the present analysis, we identified several pre-
operative risk factors closely related to in-hospital death that
might provide a valuable reference for candidate selection
and outcome prediction in pediatric VAD recipients. Al-
though no 1 predictor is a contraindication of device
insertion, children with these factors might have higher
mortality exceeding expectation, which should be carefully
considered by physicians before making a decision regarding
implantation, and this would be also useful during the
pre-operative family education encounter. Previous adult
VAD studies have indicated that healthier candidates with-
out evidence of severe functional impairment and end-organ
failure could obtain better outcomes after VAD implanta-
tion; the viewpoint was also confirmed in our study. In
pediatric patients with end-stage heart failure, complex
CHD and increased CVP are often associated with seriously
impaired right ventricular, pulmonary, hepatic, and renal
functions. Norepinephrine requirement and increased CRP
level represent more advanced circulatory failure and worse
clinical status, which might cause subsequently irreversible
organ shock sequelae due to malperfusion. In our experi-
ence, earlier VAD implantation has resulted in significantly
better survival in children. Thus, one of the most important
aspects of pediatric VAD recipient selection might be that
physicians should choose the device insertion before further
deterioration of a patient’s condition. Postponing VAD
surgery until progression to end-organ failure might signif-
icantly worsen the outcomes after implantation. Stabilizing
patients’ circulation and restoring organ function using
aggressive medical treatment or temporary mechanical sup-
port might render a child with a serious condition suitable
for VAD operation. Additionally, for patients with in-
creased pulmonary vascular resistance and impaired right
heart function, milrinone might need to be considered to
avoid additional right VAD insertion, which was also shown
to be associated with higher post-implantation mortality.
Notably, in contrast to previous pediatric VAD reports,
age and age-dependent factors were not predictive of
post-VAD survival in our study on univariable or multivari-
able analyses (3). In our cohort, approximately 70% of the
children younger than 5 years of age or those weighing 10
kg could successfully survive during the mechanical support
period. The mortality is much lower than that in previous
studies using mostly adult-sized devices, which could lead to
increased hemorrhage and thromboembolic complications
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suggests that, with the pediatric-specific VAD, younger
children could enjoy comparable benefits from VAD im-
plantation as do older adolescents.
Study limitations. First, this was a single-center, retro-
spective cohort study and therefore subject to inherent
deficiencies. Additionally, the relatively small patient sam-
ple limits study power: in our analysis, comparatively more
variables were submitted to the multivariate logistic regres-
sion analyses, and, thus, some degrees of “overfitting” might
exist; furthermore, unadjusted p values provided for univari-
able analysis should be interpreted in the context of risk for
a type I error. However, we believe that Bonferroni p value
adjustment in this exploratory analysis may lead to a
dismissal of clinically relevant variables (19). In addition, in
pediatric studies of long-term mechanical circulatory sup-
port, power limitations are inherently difficult to avoid due
to the current low device use rates. Finally, the present study
included children supported with LVAD and BVAD,
which might cause bias in our analysis. However, the
strategy in our center for BVAD implantation is to first
implant an LVAD combined with pharmacological right
heart support and then decide whether there is a need for an
additional right VAD, according to the performance of
right heart function; thus, the majority of our children
underwent LVAD implantation initially. Further analysis
has shown that the statistical significance of our risk factors
was not altered after adjustment for this confounding factor,
and the effect of this variable in the regression model was
not significant. In addition, previous reports indicated that
risk factors for outcomes in BVAD patients were similar to
those in LVAD recipients (20,21).
Conclusions
The finding of this study suggests that VAD mortality is
increased in children with CHD, pre-operative requirement
for norepinephrine, CRP level 6.3 mg/dl, and CVP 17
m Hg. Appropriate patient selection might be critical to
mproved outcomes after VAD implantation in children
ith advanced heart failure.
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